Factor v Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study

European Journal of Internal Medicine

Volumn 26, Issue 1, 2015, Pages 63-67

  Kovac, Mirjana ^a,b   Kovac, Zeljko ^c   Tomasevic, Zorica ^c   Vucicevic, Slavko ^c   Djordjevic, Valentina ^a   Pruner, Iva ^a   Radojkovic, Dragica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Blood Transfusion Institute of Serbia   (Serbia)

^c National Cancer Research Institute   (Serbia)

Author keywords

Breast cancer; Factor VIII; FV Leiden; Tamoxifen; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BLOOD CLOTTING FACTOR 5;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PREMENOPAUSE; PROSPECTIVE STUDY; VARICOSIS; VENOUS THROMBOEMBOLISM; ACTIVATED PROTEIN C RESISTANCE; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, PAPILLARY; CASE CONTROL STUDY; CHEMICALLY INDUCED; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; RISK; RISK FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; FACTOR V; FACTOR VIII; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RISK FACTORS; TAMOXIFEN; VENOUS THROMBOEMBOLISM;

EID: 84921550543     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.12.015     Document Type: Article

References (33)

1. R. Patel, C. Sharma, and V. Jordan Optimizing the antihormonal treatment and prevention of breast cancer Breast Cancer 14 2007 113 122
2. R.K. Hernandez, H.T. Sorensen, L. Pedersen, J. Jacobsen, and T.L. Lash Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism Cancer 115 2009 4442 4449
3. C.R. Meier, and J. Hershel Tamoxifen and risk of idiopathic venous thromboembolism Br J Clin Pharmacol 45 1998 608 612
4. M. Mandala, and C. Tondini Adjuvant therapy in breast cancer and venous thromboembolism Thromb. Res. 130 2012 566 570
5. K.D. Pemberton, E. Melissari, and V.V. Kakkar The influence of tamoxifen in vivo on the main natural anticoagulants Blood Coagul Fibrinolysis 4 1993 935 942
6. P.M. Mannuci, D. Bettega, and V. Chantarngkul Effect of tamoxifen on measurement of hemostasis in healthy women Arch Intern Med 156 1996 1806 1810
7. H. Rühl, L. Schroder, J. Müller, R. Fimmers, S. Sukhitashvili, and J. Welz Tamoxifen induces resistance to activated protein C Thromb Res 133 2014 886 891
8. J. Ferlay, I. Soerjomataram, and M. Ervik GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet] 2013 International Agency for Research on Cancer Lyon, France [Available from: http://globocan.iarc.fr, accessed December 2013]
9. A.A. Khorana Cancer and thrombosis: implications of guidelines for clinical practice Ann Oncol 20 2009 1619 1630
10. H. Decousus, N. Moulin, S. Quenet, V. Bost, K. Rivron-Guillot, and S. Laporte Thrombophilia and risk of venous thrombosis in patients with cancer Thromb Res 120 2007 551 561 [Suppl. 2]
11. J. Garber, S. Halabi, S. Tolaney, E. Kaplan, L. Archer, and J. Atkins Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer J Natl Cancer Ins 102 2010 942 949
12. A. Eroʇlu, and N. Akar Factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms and the risk of tamoxifen-associated thromboembolism in breast cancer patients Thromb Res 127 2011 384 385
13. M. Mandala, S. Barni, M. Prins, R. Labianca, C. Tondini, and L. Russo Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial Ann Oncol 21 2010 871 876
14. C. Ay, and I. Pabinger Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients Thromb Res 129 Suppl. 2012 S6 S9
15. A.A. Khorana Cancer-associated thrombosis: updates and controversies Hematol Am Soc Hematol Educ Prog 2012 2012 626 630
16. P.A. Kyrle, E. Minar, M. Hirschl, C. Bialonczyk, M. Stain, and B. Schneider High plasma levels of factor VIII and the risk of recurrent venous thromboembolism N Engl J Med 343 2000 457 462
17. B. Cosmi, C. Legnani, M. Cini, E. Favaretto, and G. Palareti D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis Thromb Res 122 2008 610 617
18. E. Yigit, G. Gönüllü, I. Yücel, M. Turgut, D. Erdem, and B. Cakar Relation between hemostatic parameters and prognostic/predictive factors in breast cancer Eur J Intern Med 19 2008 602 607
19. J.J. Auwerda, P. Sonneveld, M.P. de Maat, and F.W. Leebeek Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma Haematologica 92 2007 279 280
20. M. Dogan, A. Demirkazik, N. Konuk, B. Yalcin, A. Buyukcelik, and G. Utkan The effect of venous thromboembolism on survival of cancer patients and its relationship with serum levels of factor VIII and vascular endothelial growth factor: a prospective matched-paired study Int J Biol Markers 21 2006 206 210
21. UICC International Union Against Cancer L.K. Sobin, M.K. Gospodarowicz, Ch. Wittekind, TNM classification of malignant tumors 7th ed. 2009 Wiley-Blackwell NewYork
22. T. Koster, A.D. Blann, E. Briet, J.P. Vandenbroucke, and F.R. Rosendal Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis Lancet 345 1995 152 155
23. CLSI Collection, transport, and processing of blood specimens for Testing plasma-based coagulation assays and molecular hemostasis assays; approved guideline - Fifth edition. CLSI document H21-A5 2008 Wayne, PA Clinical and Laboratory Standards Institute
24. R.M. Bertina, B.P.C. Koeleman, T. Koster, F.R. Rosendaal, R.J. Dirven, and H. de Ronde Mutation in blood coagulation factor V associated with resistance to activated protein C Nature 369 1994 64 67
25. S.R. Poort, F.R. Rosendaal, P.H. Reitsma, and R.M. Bertina A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis Blood 88 1996 3698 3703
26. C. Duggan, K. Marriot, R. Edwards, and J. Cuzick Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer J Clin Oncol 21 2003 3588 3593
27. N. Abramson, J. Constantino, J. Garber, N. Barliner, L.D. Wickerham, and N. Wolmark Effect of factor V Leiden and prothrombin G20210A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial J Natl Cancer Inst 98 2006 904 910
28. J. Cuzick Tamoxifen and the factor V Leiden mutation J Natl Cancer Inst 102 2010 918 919
29. R. Vormitag, R. Simanek, C. Ay, D. Dunkler, P. Quehenberger, and C. Marosi High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study Arterioscler Thromb Vasc Biol 29 2009 2176 2181
30. A. Decensi, P. Maisonneuve, N. Rotmensz, D. Bettega, A. Costa, and V. Sacchini Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial Circulation 111 2005 650 656
31. B. Fisher, J.P. Costantino, D.L. Wickerham, R.S. Cecchini, W.M. Cronin, and A. Robidoux Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 97 2005 1652 1662
32. H.K. Chew, T. Wun, D.J. Harvey, H. Zhou, and R.H. White Incidence of venous thromboembolism and the impact on survival in breast cancer patients J Clin Oncol 25 2007 70 76
33. A.A. Ontilio, S.A. Doi, J.M. Engel, I. Glurich, J. Johnson, and R. Berg Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience Thromb Res 130 2012 27 31